Therapeutic Response

TSC1 oncogenic variants status confers therapeutic sensitivity to Everolimus in patients with Renal Angiomyolipoma.

Statements

Source and description
Afinitor (everolimus) [package insert]. FDA. The U.S. Food and Drug Administration granted approval to everolimus for the treatment of adult patients with renal angiomyolipoma and tuberous sclerosis complex (TSC), not requiring immediate surgery.